BioCardia ( (BCDA) ) has shared an update.
On May 6, 2025, BioCardia, Inc. announced that the University of Wisconsin in Madison has begun enrolling patients with ischemic heart failure in the ongoing pivotal Phase 3 CardiAMP HF II trial. This study is evaluating the CardiAMP cell therapy product for treating patients with ischemic heart failure with reduced ejection fraction and elevated cardiac stress markers. The trial aims to confirm the safety and efficacy of the therapy, which has shown promising results in improving survival and quality of life for heart failure patients. The study’s advancements include refined treatment dose definitions and improvements to the Helix system, potentially expanding patient eligibility and treatment effectiveness.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia’s overall stock score reflects significant financial challenges and risks, despite promising technical indicators and recent corporate developments. The ongoing financial instability and unattractive valuation are key constraints, but positive trial results and corporate events offer a glimmer of potential future growth.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. The company offers biotherapeutic platforms including CardiAMP autologous and CardiALLO allogeneic cell therapies, with three clinical stage product candidates in development. These therapies are supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Average Trading Volume: 80,111
Technical Sentiment Signal: Sell
Current Market Cap: $13.65M
Learn more about BCDA stock on TipRanks’ Stock Analysis page.